Pall Corporation, a global leader in filtration, separation and purification, has strengthened their commitment to advancing the drug production industry through key technology innovations and partnerships leading in to 2018. This commitment includes several recent high-profile partnership announcements in late 2017, including opening a joint laboratory for continuous manufacturing of monoclonal antibodies (mAb) with WuXi Biologics in Shanghai, becoming a key technology contributor for training sessions at the BioFactory Competence Center located in Fribourg, Switzerland, and launching Continuous Bioprocessing Leadership Forums that deliver actionable education to current and prospective customers.
“Over the past decade, our team has created the most comprehensive portfolio of products and services available to support drug manufacturers at any scale. With a truly unique range of traditional stainless steel and single-use offerings, through to semi- and fully-continuous operations, we are now more focused than ever on building key industry partnerships,” said Mario Philips, Vice President and General Manager at Pall Life Sciences, Biopharm.
From process development to production, Pall offers a range of products and services that are tailored to offer each customer their own total solution. Recent Cadence continuous bioprocessing product line introductions deliver integrated single-use technology platforms that ensure process flexibility and eliminate contamination concerns. Regardless of process type, the full portfolio is built to enable reductions in costs and the manufacturing space required at a facility, while increasing efficiency and the quality of production.
To learn more about the full portfolio of products and services, please visit: www.pall.com/biopharm.
SOURCE: Pall Life Sciences